Endoscopy 2021; 53(06): 664
DOI: 10.1055/a-1327-2359
Letter to the editor

Too early to aʼMUSE!

Department of Gastroenterology, Topiwala National Medical College and B.Y.L Nair hospital, Mumbai, India
,
Ravi Thanage
Department of Gastroenterology, Topiwala National Medical College and B.Y.L Nair hospital, Mumbai, India
,
Qais Contractor
Department of Gastroenterology, Topiwala National Medical College and B.Y.L Nair hospital, Mumbai, India
,
Pravin Rathi
Department of Gastroenterology, Topiwala National Medical College and B.Y.L Nair hospital, Mumbai, India
› Author Affiliations

Recently, transoral endoscopic techniques have been offered to patients with gastroesophageal reflux disease (GERD) after medical therapy ahead of surgery. These techniques aim to achieve efficacy similar to surgery and are less invasive; however, they are challenging and their long-term safety data are sparse. Testoni et al. recently described 37 patients with GERD undergoing transoral incisionless fundoplication (TIF) using the Medigus ultrasonic surgical endostapler (MUSE) [1]. There was significant benefit in terms of improvement in their subjective scores (65 % – 75 %). Similar improvement was seen in a study by Kim et al. [2].

However, of the patients enrolled in the study of Testoni et al., 11 had grade A esophagitis (low grade), and 23 had non-erosive esophagitis, which makes erosive esophagitis a softer indication for MUSE. There were 31 patients with Hill grade II of the gastroesophageal flap valve (GEFV), and only five had grade III. Recently, Quach et al. described a correlation between abnormal GEFV (III and IV) and the severity of GERD [3]. Over the years, studies have shown that GEFV grades I and II are normal variants across populations [4] [5].

Another aspect that needs to be highlighted here is that pH-impedance recording done at the end of study showed non-significant improvement. Moreover, only 13 patients underwent 24-hour pH-impedance recording at the end of 12 months. This is in contrast to the sample size at the end of study, where 20 patients were considered in the per-protocol analysis (as shown in the authors’ Table 1c).

This brings us to the core issue of the selection of the ideal patients for TIF. Given the complexity, availability, and cost of MUSE, it would be better focused in patients with erosive esophagitis (Los Angeles grade C & D), GEFV grade III or IV, and needs to show objective improvement of pH-impedance parameters to have a strong recommendation. Future double-blind studies will be helpful to see the actual technical success and clinical outcomes.



Publication History

Publication Date:
26 May 2021 (online)

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany